ViewRay Appoints Industry Veteran James Alecxih as Chief Commercial Officer
Mr. Alecxih to Lead Company's Commercial Expansion CLEVELAND, Oct. 2, 2018 -- (Healthcare Sales &Marketing Network) -- ViewRay, Inc. (Nasdaq: VRAY), maker of the MRIdian, which combines MRI and external-beam radiation therapy to simultaneously image ... Devices, Oncology, Radiology, Personnel ViewRay, MRIdian, radiation therapy, radiotherapy
Abstract Many different therapeutic options are available for locally recurrent prostate cancer (PCa). However, standard treatment has not yet been established. We conducted a partial prostate re-irradiation (PPR) program for the treatment of isolated and limited-size intraprostatic recurrences, in patients who previously underwent external beam radiation therapy (EBRT) as primary treatment for prostatic cancer (PCa). The analysis of this experience in terms of feasibility, toxicity, and efficacy is reported. The inclusion criteria of this retrospective analysis were: previous definitive EBRT, evidence of biochemi...
Conclusions: Recent advanced treatment modalities have improved the probability of globe salvage. However, enucleation remains an important life-saving intervention in many advanced cases. PMID: 33005446 [PubMed]
CONCLUSION: Prostate cancer treatment choices differ substantially between men diagnosed in private and public health services in Victoria. These differences are not explained by disease severity or comorbidity. PMID: 32996611 [PubMed - as supplied by publisher]
Prostate cancer is the most common malignancy in North American males and the second leading cause of cancer death. External beam radiation therapy plays an important role in the clinical management of prostate cancer of various stages. Currently, image-guided target localization for intensity-modulated radiation therapy (IMRT) of prostate cancer has become a routine procedure, and plays an essential role in dose escalation and hypo-fractionation clinical trials, especially for those that employ stereotactic body radiation therapy (SBRT) techniques.
ConclusionCystus ® and sage tea have a similar effect on the occurrence of radiation-induced mucositis regarding latency and incidence. Cystus® tea mouthwash solution is tolerated well and can be applied in addition to intensive oral care and hygiene along with the application of fluorides.
A mainstay therapy for pain relief from uncomplicated bone metastases is external beam radiation therapy. Single fraction radiation therapy (SFRT) is more convenient and cost-effective, causes fewer acute side effects, and is equivalent to multiple fraction radiation therapy for pain relief. Despite these advantages, radiation oncologists seldom prescribe SFRT.
Cancer-related fatigue (CRF), a prevalent and potentially debilitating symptom among cancer patients, is a side effect of external beam radiotherapy (EBRT). Even when targeting organs unrelated to caloric intake or the CNS, radiotherapy can increase CRF, a complex and poorly understood toxicity resulting from patient-specific, systemic therapy-related, and radiation specific factors.
The standard of care for patients with endometrial cancer typically involves upfront surgery. External beam radiotherapy, brachytherapy, and/or chemotherapy are implemented in the adjuvant setting based on individual risk factors. In the subset of women who are unable to receive surgery due to medical comorbidities or tumor-related factors, external beam radiation and/or uterine brachytherapy can be employed in the definitive setting.
External beam radiation therapy (EBRT) is utilized in a subset of high-risk patients with differentiated thyroid cancer (DTC). Proton beam therapy is an attractive modality given the potential enhanced biological dose with improved sparing of normal structures.
Anaplastic thyroid carcinoma (ATC) accounts for less than 5% of thyroid cancers and is associated with rapid disease progression and very poor treatment outcomes. For locally advanced tumors, external beam radiotherapy (EBRT) administered after surgical resection or as primary treatment in operable disease, is considered the standard of care. We evaluated the outcomes following aggressive management of locoregional disease with multimodality therapy in the era of intensity-modulated radiation therapy (IMRT).